

June 15, 2021

Markus Warmuth  
President and Chief Executive Officer  
Monte Rosa Therapeutics, Inc.  
645 Summer Street, Suite 102  
Boston, MA 02210

Re: Monte Rosa

Therapeutics, Inc.

Amendment No. 1 to

Registration Statement on Form S-1

Filed June 9, 2021  
File No. 333-256773

Dear Dr. Warmuth:

We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Amendment 1 to Form S-1 Filed on June 9, 2021

Dilution, page 85

1. Please revise your calculations for your net tangible and pro forma net tangible book value (deficit) per share as of March 31, 2021 to utilize 6,079,905 outstanding underlying the calculation disclosed on pages F-30 and F-32 as of March 31, 2021 rather than 7,699,359 shares outstanding, which are a result of the unvested shares of restricted stock being classified as issued but not outstanding.

Markus Warmuth  
FirstName  
Monte RosaLastNameMarkus  
Therapeutics, Inc.Warmuth

Comapany  
June NameMonte Rosa Therapeutics, Inc.  
15, 2021

June 15,  
Page 2 2021 Page 2  
FirstName LastName

You may contact Tara Harkins at 202-551-3639 or Lynn Dicker at 202-551-3616 if you have questions regarding comments on the financial statements and related matters. Please contact Kasey Robinson at 202-551-5880 or Jeffrey Gabor at 202-551-2544 with any other questions.

Sincerely,

Division of Corporation

Office of Life Sciences

Finance

cc: Robert E. Puopolo, Esq.

